{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T22:47:38Z","timestamp":1765234058845,"version":"build-2065373602"},"reference-count":52,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"research funds of the Clinic for Medical Oncology and Hematology, Cantonal Hospital St. Gallen"},{"name":"the Department for Medical Oncology and Hematology, Cantonal Hospital Graub\u00fcnden, Chur"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: The AML60+ score has been proposed for risk stratification in intensively treated elderly patients with acute myeloid leukemia (AML) or high-risk myelodysplastic neoplasms (MDS). Its prognostic impact in patients treated with hypomethylating agents (HMA) is unknown. Methods: Patients \u2265 60 years of age diagnosed with AML or MDS\/AML according to ICC2022 were eligible for this retrospective and multicenter chart review if they had received at least one cycle of HMA-based treatment. Results: A cohort of 142 patients was analyzed. During follow-up (median 8 months), 114 patients died. The molecular Prognostic Score (mPRS) was available for 121 patients, the European Leukemia Net (ELN) 2022 classification for 117 patients, and the AML60+ for 105 patients. According to AML60+, 33 patients (31.4%) were classified as very poor risk, 36 (34.3%) as poor risk, and 34 (32.4%) as intermediate risk. Two patients (1.9%) were classified as favorable. Median overall survival (OS) was 21.7 months (mo) for the combined intermediate\/favorable group, 7 mo for the poor risk group and 3 mo for the very poor risk group (p &lt; 0.0001). Cox regression analysis (reference category: very poor) showed a significantly lower risk of death for both intermediate\/favorable risk patients (HR 0.17, 95% CI 0.10\u20130.31, p &lt; 0.001) and poor risk patients (HR 0.47, 95% CI 0.28\u20130.78, p = 0.004). The concordance score was 0.67 for AML60+, 0.60 for mPRS, and 0.58 for ELN2022. Conclusions: The AML60+ may represent a useful prognostic tool for elderly AML patients treated with HMA-based therapies. In particular, it could help to identify a group with a relatively favorable prognosis that is not clearly identified by the ELN2022 or the mPRS risk classification. However, analyses of larger cohorts are necessary to confirm our findings.<\/jats:p>","DOI":"10.3390\/cancers17162658","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T15:16:37Z","timestamp":1755184597000},"page":"2658","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic Impact of the AML60+ Score for Elderly Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Retrospective Multicentric Analysis"],"prefix":"10.3390","volume":"17","author":[{"given":"Verena","family":"Petermichl","sequence":"first","affiliation":[{"name":"Clinic for Medical Oncology and Hematology, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Fuchs","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Cantonal Hospital Graub\u00fcnden, 7000 Chur, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Weber","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin","family":"Gobat","sequence":"additional","affiliation":[{"name":"Swiss Cancer Institute, Statistics Unit, 3008 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4995-4505","authenticated-orcid":false,"given":"Charlotte","family":"Micheloud","sequence":"additional","affiliation":[{"name":"Swiss Cancer Institute, Statistics Unit, 3008 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Graf","sequence":"additional","affiliation":[{"name":"Center for Laboratory Medicine, St. Gallen, 9007 St. Gallen, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yannick","family":"Gerth","sequence":"additional","affiliation":[{"name":"Center for Laboratory Medicine, St. Gallen, 9007 St. Gallen, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7054-0174","authenticated-orcid":false,"given":"Jeroen S.","family":"Goede","sequence":"additional","affiliation":[{"name":"Medical Oncology and Hematology, Cantonal Hospital Winterthur, 8400 Winterthur, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Lehmann","sequence":"additional","affiliation":[{"name":"Clinic for Medical Oncology and Hematology, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland"},{"name":"Institute of Pathology, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Driessen","sequence":"additional","affiliation":[{"name":"Clinic for Medical Oncology and Hematology, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich J. M.","family":"Mey","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Cantonal Hospital Graub\u00fcnden, 7000 Chur, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9677-9885","authenticated-orcid":false,"given":"Richard","family":"Cathomas","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Cantonal Hospital Graub\u00fcnden, 7000 Chur, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Cogliatti","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6859-3090","authenticated-orcid":false,"given":"Tobias","family":"Silzle","sequence":"additional","affiliation":[{"name":"Clinic for Medical Oncology and Hematology, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland"},{"name":"Department of Medical Oncology and Hematology, Cantonal Hospital Graub\u00fcnden, 7000 Chur, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","article-title":"Acute Myeloid Leukaemia","volume":"401","author":"DiNardo","year":"2023","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.canep.2016.03.011","article-title":"Myeloid Malignancies in the Real-World: Occurrence, Progression and Survival in the UK\u2019s Population-Based Haematological Malignancy Research Network 2004\u201315","volume":"42","author":"Roman","year":"2016","journal-title":"Cancer Epidemiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and Management of AML in Adults: 2022 Recommendations from an International Expert Panel on Behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/ajh.27625","article-title":"Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management","volume":"100","author":"Shimony","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Ucciero, A., Pagnoni, F., Scotti, L., Pisterna, A., Barone-Adesi, F., Gaidano, G., Patriarca, A., and Lunghi, M. (2023). Venetoclax with Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Survival Data from Real-World Studies. Cancers, 15.","DOI":"10.3390\/cancers15184618"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Wang, Y., Chen, Y., Ji, D., Ge, L., Zhang, Y., Liu, L., Jiang, L., Jin, F., and Xia, L. (2025). Meta-Analysis on the Effectiveness and Safety of Venetoclax-Based Combination Therapy with Hypomethylation in Acute Myeloid Leukemia. Eur. J. Med. Res., 30.","DOI":"10.1186\/s40001-025-02571-x"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Madarang, E., Lykon, J., Zhao, W., Sekeres, M.A., Bradley, T., Chandhok, N.S., Taylor, J., Venugopal, S., Koru-Sengul, T., and Iyer, S.G. (2024). Venetoclax and Hypomethylating Agents in Octogenarians and Nonagenarians with Acute Myeloid Leukemia. Blood Neoplasia, 1.","DOI":"10.1016\/j.bneo.2024.100016"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1182\/blood.2024024009","article-title":"How I Treat Patients with AML Using Azacitidine and Venetoclax","volume":"145","author":"Wei","year":"2025","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-Term Follow-up of VIALE-A: Venetoclax and Azacitidine in Chemotherapy-Ineligible Untreated Acute Myeloid Leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s00277-024-05700-4","article-title":"Very Long-Term Efficacy of Venetoclax Combined with Hypomethylating Agents in Two AML Elderly: Is It the Time for Treatment Discontinuation Strategies?","volume":"103","author":"Niscola","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1182\/bloodadvances.2022007083","article-title":"Treatment-Free Remission after Ceasing Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia","volume":"6","author":"Chua","year":"2022","journal-title":"Blood Adv."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1002\/ajh.27417","article-title":"Outcomes of Acute Myeloid Leukemia Patients Who Responded to Venetoclax and Azacitidine and Stopped Treatment","volume":"99","author":"Garciaz","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood.2024024944","article-title":"Genetic Risk Stratification and Outcomes among Treatment-Naive Patients with AML Treated with Venetoclax and Azacitidine","volume":"144","author":"Pratz","year":"2024","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2023011757","article-title":"Prognostic Risk Signature in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax","volume":"8","author":"Bataller","year":"2024","journal-title":"Blood Adv."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.2024025409","article-title":"Genetic Risk Classification for Adults with AML Receiving Less-Intensive Therapies: The 2024 ELN Recommendations","volume":"144","author":"DiNardo","year":"2024","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.1182\/bloodadvances.2024013685","article-title":"Beat-AML 2024 ELN\u2013Refined Risk Stratification for Older Adults with Newly Diagnosed AML given Lower-Intensity Therapy","volume":"8","author":"Hoff","year":"2024","journal-title":"Blood Adv."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/ajh.27564","article-title":"Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent","volume":"100","author":"Gangat","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.1200\/JCO.23.02631","article-title":"Risk Stratification in Older Intensively Treated Patients With AML","volume":"42","author":"Versluis","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating Morphologic, Clinical, and Genomic Data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/bloodadvances.2020002846","article-title":"Ibrutinib Added to 10-Day Decitabine for Older Patients with AML and Higher Risk MDS","volume":"4","author":"Huls","year":"2020","journal-title":"Blood Adv."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Griffioen, M.S., de Leeuw, D.C., Janssen, J.J.W.M., and Smit, L. (2022). Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies. Cancers, 14.","DOI":"10.3390\/cancers14143456"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/hematology.2024000540","article-title":"Mutation- and MRD-Informed Treatments for Transplant-Ineligible Patients","volume":"2024","author":"Lachowiez","year":"2024","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1080\/10428194.2016.1246726","article-title":"Differential Response to Hypomethylating Agents Based on Sex: A Report on Behalf of the MDS Clinical Research Consortium (MDS CRC)","volume":"58","author":"DeZern","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1016\/S2352-3026(22)00323-4","article-title":"A Sex-Informed Approach to Improve the Personalised Decision Making Process in Myelodysplastic Syndromes: A Multicentre, Observational Cohort Study","volume":"10","author":"Maggioni","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Hilberink, J.R., van Zeventer, I.A., Chitu, D.A., Pabst, T., Klein, S.K., Stussi, G., Griskevicius, L., Valk, P.J.M., Cloos, J., and van de Loosdrecht, A.A. (2023). Age and Sex Associate with Outcome in Older AML and High Risk MDS Patients Treated with 10-Day Decitabine. Blood Cancer J., 13.","DOI":"10.1038\/s41408-023-00850-6"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41375-023-02068-8","article-title":"Sex-Associated Differences in Frequencies and Prognostic Impact of Recurrent Genetic Alterations in Adult Acute Myeloid Leukemia (Alliance, AMLCG)","volume":"38","author":"Ozga","year":"2024","journal-title":"Leukemia"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Othman, J., Lam, H.P.J., Leong, S., Basheer, F., Abdallah, I., Fleming, K., Mehta, P., Yassin, H., Laurie, J., and Austin, M. (2024). Real-World Outcomes of Newly Diagnosed AML Treated with Venetoclax and Azacitidine or Low-Dose Cytarabine in the UK NHS. Blood Neoplasia, 1.","DOI":"10.1016\/j.bneo.2024.100017"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1038\/s41375-024-02435-z","article-title":"Acute Myeloid Leukemia: Does Sex Matter?","volume":"38","author":"Tettero","year":"2024","journal-title":"Leukemia"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41375-024-02175-0","article-title":"Hypomethylating Agents plus Venetoclax Compared with Intensive Induction Chemotherapy Regimens in Molecularly Defined Secondary AML","volume":"38","author":"Shimony","year":"2024","journal-title":"Leukemia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-025-02625-3","article-title":"Impact of Myelodysplasia-Related Gene Mutations and Residual Mutations at Remission in Venetoclax\/Azacitidine for AML","volume":"39","author":"Ikoma","year":"2025","journal-title":"Leukemia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/cncr.34609","article-title":"Prediction of Survival with Lower Intensity Therapy among Older Patients with Acute Myeloid Leukemia","volume":"129","author":"Sasaki","year":"2023","journal-title":"Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Bewersdorf, J.P., and Zeidan, A.M. (2020). Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments?. Cells, 9.","DOI":"10.3390\/cells9102310"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1007\/s00277-024-05840-7","article-title":"Do NPM1 and FLT3-ITD Mutations Modify Prognosis in Patients Treated with Non-Intensive Regimens?","volume":"103","author":"Boluda","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1080\/1120009X.2022.2097433","article-title":"Hypomethylating Agents Combined with Low-Dose Chemotherapy for Elderly Patients with Acute Myeloid Leukaemia Unfit for Intensive Chemotherapy: A Real-World Clinical Experience","volume":"35","author":"Chen","year":"2023","journal-title":"J. Chemother."},{"key":"ref_36","first-page":"3074","article-title":"Prognostic Implication of FLT3 and N-RAS Gene Mutations in Acute Myeloid Leukemia","volume":"93","author":"Kiyoi","year":"1999","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","article-title":"The Presence of a FLT3 Internal Tandem Duplication in Patients with Acute Myeloid Leukemia (AML) Adds Important Prognostic Information to Cytogenetic Risk Group and Response to the First Cycle of Chemotherapy: Analysis of 854 Patients from the United Kingdom Medical Research Council AML 10 and 12 Trials","volume":"98","author":"Kottaridis","year":"2001","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Shahzad, M., Amin, M.K., Daver, N.G., Shah, M.V., Hiwase, D., Arber, D.A., Kharfan-Dabaja, M.A., and Badar, T. (2024). What Have We Learned about TP53-Mutated Acute Myeloid Leukemia?. Blood Cancer J., 14.","DOI":"10.1038\/s41408-024-01186-5"},{"key":"ref_39","first-page":"1304","article-title":"Clinical Interrogation of TP53 Aberrations and Its Impact on Survival in Patients with Myeloid Neoplasms","volume":"110","author":"Senapati","year":"2025","journal-title":"Haematologica"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Badar, T., Nanaa, A., Atallah, E., Shallis, R.M., Guilherme, S.d.C.C., Goldberg, A.D., Saliba, A.N., Patel, A., Bewersdorf, J.P., and DuVall, A.S. (2024). Comparing Venetoclax in Combination with Hypomethylating Agents to Hypomethylating Agent-Based Therapies for Treatment Naive TP53-Mutated Acute Myeloid Leukemia: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood Cancer J., 14.","DOI":"10.1038\/s41408-024-01000-2"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1182\/blood-2011-08-375758","article-title":"TP53 Alterations in Acute Myeloid Leukemia with Complex Karyotype Correlate with Specific Copy Number Alterations, Monosomal Karyotype, and Dismal Outcome","volume":"119","author":"Schlenk","year":"2012","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1002\/cncr.30203","article-title":"TP53 Mutations in Newly Diagnosed Acute Myeloid Leukemia: Clinicomolecular Characteristics, Response to Therapy, and Outcomes","volume":"122","author":"Kadia","year":"2016","journal-title":"Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-22-1183","article-title":"Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1080\/10428194.2021.1973675","article-title":"Prognostic Impact of Conventional Cytogenetics in Acute Myeloid Leukemia Treated with Venetoclax and Decitabine","volume":"62","author":"Venugopal","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.3324\/haematol.2022.281214","article-title":"Molecular Predictors of Response to Venetoclax plus Hypomethylating Agent in Treatment-Na\u00efve Acute Myeloid Leukemia","volume":"107","author":"Gangat","year":"2022","journal-title":"Haematologica"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.3324\/haematol.2022.282677","article-title":"Outcome of Patients with Acute Myeloid Leukemia Following Failure of Frontline Venetoclax plus Hypomethylating Agent Therapy","volume":"108","author":"Gangat","year":"2023","journal-title":"Haematologica"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1007\/s00277-025-06399-7","article-title":"Selective Efficacy of Venetoclax in Unfit Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Gene Mutations under Low-Intensity Therapy","volume":"104","author":"Lin","year":"2025","journal-title":"Ann. Hematol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Lai, A., Liu, W., Zhou, C., Li, Y., Wei, S., Liu, K., Gong, B., Gong, X., Liu, Y., and Zhang, G. (2025). Prognostic Impact of Co-Mutations in Adults with IDH1\/2-Mutated Acute Myeloid Leukemia. Blood Sci., 7.","DOI":"10.1097\/BS9.0000000000000231"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Hoff, F.W., Huang, Y., Welkie, R.L., Swords, R.T., Traer, E., Stein, E.M., Lin, T.L., Patel, P.A., Robert H Collins, J., and Baer, M.R. (2025). Molecular Characterization of Newly Diagnosed Acute Myeloid Leukemia Patients Aged 60 Years or Older: A Report from the Beat AML Clinical Trial. Blood Cancer J., 15.","DOI":"10.1038\/s41408-025-01258-0"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Yao, Y., Zhou, Y., Zhuo, N., Xie, W., Meng, H., Lou, Y., Mao, L., Tong, H., Qian, J., and Yang, M. (2024). Co-mutation landscape and its prognostic impact on newly diagnosed adult patients with NPM1-mutated de novo acute myeloid leukemia. Blood Cancer J., 14.","DOI":"10.1038\/s41408-024-01103-w"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular Patterns of Response and Treatment Failure after Frontline Venetoclax Combinations in Older Patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/ajh.26724","article-title":"Differential Prognostic Impact of RUNX1 Mutations According to Frontline Therapy in Patients with Acute Myeloid Leukemia","volume":"97","author":"Venugopal","year":"2022","journal-title":"Am. J. Hematol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/16\/2658\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:27:51Z","timestamp":1760034471000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/16\/2658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":52,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["cancers17162658"],"URL":"https:\/\/doi.org\/10.3390\/cancers17162658","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2025,8,14]]}}}